viewMedlab Clinical Ltd

Medlab Clinical expects clinical trial data next month

Medlab is a revenue generating research company with an aggressive product development pipeline.

Medlab Clinical Ltd - Medlab Clinical expects clinical trial data next month
The number of NanaBis™ and NanaBidial™ cannabis bottles being dispenses continues to grow

Medlab Clinical Ltd (ASX:MDC) continues to focus on progressing its cannabinoid-based drug candidates in 2020 led by the cancer pain drug NanaBis™.

Clinical trials will be progressed on the road towards the commercial opportunity that a registered drug would represent.

Notably, during December 2019, the NanaBis™ cancer pain trial at Royan North Shore Hospital was completed.

The highly significant data from the phase 2 clinical trials is expected by the end of February 2020.

Global conferences to discuss the findings of the trial are already being booked to include Australia, USA and Europe and phase 3 clinical trials are in design.

Quarterly revenue and volume growth continues

Revenues from our core cannabis-based medicines NanaBis™ and NanaBidial™ are starting to feature more prominently in quarterly incomes.

Both products are available in Australia via the Australian Government’s compassionate program (SAS).

Medlab generates the majority of its current revenue through the sales of its nutraceutical product range which features 25 premium formulations.

The nutraceuticals business is expanding into new revenue territories including the US, UK and Asia where Medlab expects to see revenue flow over the next few months without material operating or capital expenditure.

As Medlab progresses its core cannabis-based medicine portfolio, it expects them to contribute more materially to company revenue.

Quick facts: Medlab Clinical Ltd

Price: 0.135 AUD

Market: ASX
Market Cap: $31.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...



Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 8/5/19

2 min read